Lista de obras -

Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry.

artículo científico publicado en 2013

Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?

artículo científico publicado en 2018

Anal metastasis from breast cancer: a case report and review of the literature.

artículo científico

Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis

scientific article published on 25 June 2019

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.

artículo científico publicado en 2018

Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study

artículo científico publicado en 2015

Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients

artículo científico publicado en 2014

Carcinogenesis of pancreatic adenocarcinoma: precursor lesions.

artículo científico publicado en 2013

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.

artículo científico publicado en 2009

Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis.

artículo científico publicado en 2012

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.

artículo científico publicado en 2014

Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger

artículo científico publicado en 2015

Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer

artículo científico publicado en 2016

Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone

article

Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.

artículo científico

Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer

scientific article published on 07 August 2018

Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.

artículo científico publicado en 2018

Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer.

artículo científico publicado en 2012

Evaluation of Social Support, Quality of Life, and Body Image in Women with Breast Cancer.

artículo científico publicado en 2016

Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study

artículo científico publicado en 2014

How can we improve prognostic models in renal cell carcinoma?

artículo científico publicado en 2015

Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy

artículo científico publicado en 2019

Is there a role for immunotherapy in malignant pleural mesothelioma?

artículo científico publicado en 2018

Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?

artículo científico publicado en 2019

Lenvatinib for the treatment of renal cell carcinoma.

artículo científico publicado en 2018

Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared.

artículo científico publicado en 2017

Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.

artículo científico publicado en 2017

Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry.

artículo científico publicado en 2012

Long-term survival in small cell lung cancer: a case report and review of the literature.

artículo científico publicado en 2014

Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience

scientific article published on 17 July 2018

Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.

artículo científico publicado en 2014

M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis.

artículo científico publicado en 2010

Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.

artículo científico publicado en 2013

Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer

artículo científico publicado en 2017

Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK-Positive Non-Small Cell Lung Cancer (NSCLC).

artículo científico publicado en 2016

Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.

artículo científico publicado en 2014

Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies

artículo científico publicado en 2014

New cancer drugs: the Italian unsatisfactory solution

artículo científico publicado en 2014

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

scientific article published on 01 December 2018

Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.

artículo científico

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223

artículo científico publicado en 2018

Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor

artículo científico publicado en 2006

Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel

artículo científico publicado en 2019

Poor survival in prostate cancer patients with primary refractoriness to docetaxel.

artículo científico publicado en 2013

Possible applications of circulating tumor cells in patients with non small cell lung cancer.

artículo científico publicado en 2016

Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.

artículo científico publicado en 2013

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.

artículo científico publicado en 2014

Progress and challenges in the treatment of small cell lung cancer

artículo científico publicado en 2017

Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation

artículo científico publicado en 2011

Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma

artículo científico publicado en 2014

Reflections about off-label use of anticancer drugs

scientific article published on 01 October 2012

Role and limits of salvage chemotherapy in breast cancer patients treated with high-dose chemotherapy

artículo científico publicado en 2003

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

artículo científico publicado en 2019

Selected case from the Arkadi M. Rywlin International Pathology Slide Series: Leiomyomatosis peritonealis disseminata: report of 3 cases with extensive review of the literature

artículo científico

Somatostatin Analog Therapy in Small Cell Lung Cancer

artículo científico publicado en 2016

Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.

artículo científico publicado en 2013

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.

artículo científico publicado en 2016

Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

artículo científico publicado en 2016

The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.

artículo científico

The clinical impact of a cardiologic follow-up in breast cancer survivors: an observational study.

artículo científico publicado en 2010

The epidermal growth factor receptors as biological targets in penile cancer.

artículo científico publicado en 2014

The evolving landscape in advanced penile cancer

artículo científico publicado en 2015

The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.

artículo científico publicado en 2016

The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer

artículo científico publicado en 2019

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).

artículo científico publicado en 2018

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

artículo científico publicado en 2010

Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma.

artículo científico publicado en 2018

When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs.

artículo científico publicado en 2015

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?

artículo científico publicado en 2014

Lista de obras de

Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry.

Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?

Anal metastasis from breast cancer: a case report and review of the literature.

Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.

Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study

Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients

Carcinogenesis of pancreatic adenocarcinoma: precursor lesions.

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.

Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis.

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.

Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger

Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer

Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone

Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.

Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer

Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.

Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer.

Evaluation of Social Support, Quality of Life, and Body Image in Women with Breast Cancer.

Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study

How can we improve prognostic models in renal cell carcinoma?

Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy

Is there a role for immunotherapy in malignant pleural mesothelioma?

Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?

Lenvatinib for the treatment of renal cell carcinoma.

Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared.

Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.

Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry.

Long-term survival in small cell lung cancer: a case report and review of the literature.

Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience

Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.

M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis.

Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.

Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer

Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK-Positive Non-Small Cell Lung Cancer (NSCLC).

Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.

Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies

New cancer drugs: the Italian unsatisfactory solution

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223

Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor

Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel

Poor survival in prostate cancer patients with primary refractoriness to docetaxel.

Possible applications of circulating tumor cells in patients with non small cell lung cancer.

Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.

Progress and challenges in the treatment of small cell lung cancer

Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation

Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma

Reflections about off-label use of anticancer drugs

Role and limits of salvage chemotherapy in breast cancer patients treated with high-dose chemotherapy

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

Selected case from the Arkadi M. Rywlin International Pathology Slide Series: Leiomyomatosis peritonealis disseminata: report of 3 cases with extensive review of the literature

Somatostatin Analog Therapy in Small Cell Lung Cancer

Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.

Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.

The clinical impact of a cardiologic follow-up in breast cancer survivors: an observational study.

The epidermal growth factor receptors as biological targets in penile cancer.

The evolving landscape in advanced penile cancer

The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.

The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma.

When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs.

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?